Oppenheimer Upgrades Edwards Lifesciences to Outperform, Announces $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia has upgraded Edwards Lifesciences (NYSE:EW) from Perform to Outperform and set a price target of $90.
September 26, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences has been upgraded to Outperform by Oppenheimer, with a price target of $90.
The upgrade from Oppenheimer is a positive signal for Edwards Lifesciences. The new rating of Outperform suggests that the analyst believes the company will outperform the market, which could lead to an increase in the stock price. The price target of $90 also indicates a potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100